Essendon, Australia Clinical Trials

A listing of Essendon, Australia clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) provides superior efficacy in improving radiographic progression-free survival (rPFS).

Peter MacCallum Cancer Centre
 (5.2 away) Contact site
  • 0 views
  • 02 Jun, 2021
  • +394 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus ADT in participants with mHSPC. The primary hypothesis is that in participants with mHSPC, the combination of pembrolizumab plus enzalutamide plus ADT is superior to placebo plus enzalutamide plus ADT with …

Peter MacCallum Cancer Centre ( Site 0306)
 (5.4 away) Contact site
  • 272 views
  • 20 Jun, 2021
  • +222 other locations
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. PURPOSE: This randomized phase III trial is studying how well androgen deprivation therapy works in treating patients with prostate cancer.

epinephrine
orchiectomy
androgens
antiandrogen therapy
androgen suppression
Peter MacCallum Cancer Centre
 (5.9 away) Contact site
  • 401 views
  • 07 Nov, 2020
  • +8 other locations
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP plus placebo.

Peter MacCallum Cancer Centre
 (5.4 away) Contact site
  • 498 views
  • 26 Jan, 2021
  • +480 other locations
A Study of Apalutamide in Participants With High-Risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and …

adenocarcinoma of prostate
metastasis
apalutamide
androgens
antiandrogen therapy
Royal Melbourne Hospital
 (4.2 away) Contact site
  • 291 views
  • 02 Jun, 2021
  • +352 other locations
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

Primary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: To characterize the long-term efficacy of fitusiran as assessed by the frequency of: Bleeding episodes Spontaneous bleeding episodes Target joint bleeding episodes To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants …

antihemophilic factor
hemarthrosis
fitusiran
severe haemophilia a
Investigational Site Number '0360003
 (8.5 away) Contact site
  • 180 views
  • 12 Mar, 2021
  • +65 other locations
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at very high risk of recurrence.

external beam radiotherapy
luteinizing hormone-releasing hormone agonist
androgens
antiandrogen therapy
gonadorelin
Peter MacCallum Cancer Centre
 (5.4 away) Contact site
  • 62 views
  • 19 Apr, 2021
  • +30 other locations
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

Pharmacy Services, Peter MacCallum Cancer Centre
 (3.8 away) Contact site
  • 4293 views
  • 27 May, 2021
  • +497 other locations
Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec With Prophylactic Steroids in Hemophilia A

This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe hemophilia A.

Alfred Hospital
 (6.7 away) Contact site
  • 0 views
  • 16 May, 2021
  • +8 other locations
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa alone.

Saint Vincent's Hospital - Melbourne
 (5.0 away) Contact site
  • 0 views
  • 15 Jun, 2021
  • +98 other locations